

21ST EDITION



The Science and Practice of Pharmacy



0(

Δ

R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Editor: David B. Troy Managing Editor: Matthew J. Hauber Marketing Manager: Marisa A. O'Brien

Lippincott Williams & Wilkins

351 West Camden Street Baltimore, Maryland 21201-2436 USA

530 Walnut Street

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, All rights reserved. This book is protected by copyright. No part of this book any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copy. right owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any The publisher is not responsible (as a matter of product liability, negregation and principles of medical care which should not material contained herein. This publication contains information relating to general principles of medical care which should not material contained herein. This publication contains information relating by product information and package inserts should not be construed as specific instructions for individual patients. Manufacturer's product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science

Copyright 2000, 2006, by the University of the Sciences in Philadelphia

All Rights Reserved Library of Congress Catalog Card Information is available ISBN 0-7817-4673-6

The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any ingraverant contained based base

Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and / or the National Formulary (NTP) of the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the equivalent of or a substitute for the official current official USP or NF standards of strength, quality, purity, prochasing the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301) 824-7390. International customers should call (301) 714 9294

DOCKE

Find authenticated court documents without watermarks at docketalarm.com.

Contents

DOCKE.

Α

R

Μ

Α

1 Scope of Pharmacy	Par	t 1 Orientation
2 Evolution of Pharmacy 7 3 Ethics and Professionalism 20 4 The Practice of Community Pharmacy 33 5 Pharmacists in Government 40 7 Pharmacists and Public Health 51 8 Information Resources in Pharmacy and the Pharmaceutical Sciences 64 9 Clinical Drug Literature 74 10 Research 87 7 Pharmaceutical Sciences 64 10 Research 87 7 Pharmaceutical Sciences 64 11 Metrology and Pharmaceutical Calculations 99 12 Statistics 127 13 Molecular Structure, Properties, and States of Matter 162 14 Complex Formation 166 15 Thermodynamics 201 16 Solutions and Phase Equilibria 211 17 tonic Solutions and Electrolytic Equilibria 231 18 Tonicity, Osmoticity, Osmolaity, and Osmolarity 250 20 Interfacial Phenomena 200 21 Colloidal Dispers	1	Scope of Pharmacy
3 Ethics and Professionalism 24 4 The Practice of Community Pharmacy 36 5 Pharmacists in Industry 35 6 Pharmacists in Government 44 7 Pharmacists in Pharmacy and the 44 7 Pharmaceutical Sciences 54 9 Clinical Drug Literature 74 10 Research 87 9 Statistics 127 11 Metrology and Pharmaceutical Calculations 99 12 Statistics 127 13 Molecular Structure, Properties, and States of Matter 166 14 Complex Formation 186 15 Thermodynamics 201 16 Solutions and Phase Equilibria 231 17 tonic Solutions and Phase Equilibria 231 18 Tonicity, Osmoticity, Osmolaity, and Osmolarity 250 19 Chemical Kinetics 266 20 Interfacial Phenomena 280 21 Colidal Dispersions 319 22 Coarse Dispersions 319	2	Evolution of Pharmacy
4 The Practice of Community Pharmacy 33 5 Pharmacists in Industry 32 6 Pharmacists and Public Health 35 7 Pharmacists and Public Health 51 8 Information Resources in Pharmacy and the Pharmaceutical Sciences 64 9 Clinical Drug Literature 74 10 Research 87 Part 2 Pharmaceutical Calculations 99 11 Metrology and Pharmaceutical Calculations 99 12 Statistics 27 13 Molecular Structure, Properties, and States of Matter 162 14 Complex Formation 86 15 Thermodynamics 201 16 Solutions and Phase Equilibria 211 17 Ionic Solutions and Electrolytic Equilibria 231 18 Tonicity, Osmoticity, Osmolality, and Osmolarity 250 19 Chemical Kinetics 266 20 Interfacial Phenomena 280 21 Colloidal Dispersions 293 22 Coarse Dispersions 219 2	3	Ethics and Professionalism
5 Pharmacists in Industry 35 6 Pharmacists and Public Health 400 7 Pharmaceutical Sciences 64 9 Clinical Drug Literature 74 10 Research 87 Part 2 Pharmaceutical Sciences 64 9 Clinical Drug Literature 74 10 Research 87 Part 2 Pharmaceutical Calulations 99 11 Metrology and Pharmaceutical Calculations 99 12 Statistics 127 13 Molecular Structure, Properties, and States of Matter 162 14 Complex Formation 186 15 Thermodynamics 201 16 Solutions and Phase Equilibria 211 17 Ionic Solutions and Electrolytic Equilibria 231 18 Tonicity, Osmoticity, Osmolality, and Osmolarity 250 19 Chemical Kinetics 206 20 Interfacial Phenomena 280 21 Colloidal Dispersions 293 22 Caarse Dispersions 319	4	The Practice of Community Pharmacy
6 Pharmacists in Government	5	Pharmacists in Industry
7 Pharmaceutical sciences	6	Pharmacists in Government
8 Information Resources in Pharmacy and the Pharmaceutical Sciences	7	Pharmacists and Public Health51
Pharmaceutical Sciences	8	Information Resources in Pharmacy and the
9 Clinical Drug Literature		Pharmaceutical Sciences
10 Research 87 Part 2 Pharmaceutics 11 Metrology and Pharmaceutical Calculations 99 12 Statistics 127 13 Molecular Structure, Properties, and States of Matter 162 14 Complex Formation 186 15 Thermodynamics 201 16 Solutions and Phase Equilibria 211 17 Ionic Solutions and Electrolytic Equilibria 231 18 Tonicity, Osmoticity, Osmolality, and Osmolarity 250 19 Chemical Kinetics 266 20 Interfacial Phenomena 280 21 Colloidal Dispersions 293 22 Coarse Dispersions 319 23 Rheology 338 Part 3 Pharmaceutical Chemistry 361 25 Organic Pharmaceutical Chemistry 361 26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medicinals 47	9	Clinical Drug Literature
Part 2 Pharmaceutics 11 Metrology and Pharmaceutical Calculations	10	Research
11 Metrology and Pharmaceutical Calculations 99 12 Statistics 127 13 Molecular Structure, Properties, and States of Matter 162 14 Complex Formation 186 15 Thermodynamics 201 16 Solutions and Phase Equilibria 211 17 Ionic Solutions and Electrolytic Equilibria 231 18 Tonicity, Osmoticity, Osmolality, and Osmolarity 250 19 Chemical Kinetics 266 20 Interfacial Phenomena 280 21 Colloidal Dispersions 219 22 Coarse Dispersions 319 23 Rheology 338 Part 3 Pharmaceutical Chemistry 361 25 Organic Pharmaceutical Chemistry 361 26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medical Radionuclides 479 Part 4 Pharmaceutical Testing, Analysis, and Control 303	Part	2 Pharmaceutics
12 Statistics 127 13 Molecular Structure, Properties, and States of Matter 162 14 Complex Formation 186 15 Thermodynamics 201 16 Solutions and Phase Equilibria 211 17 Ionic Solutions and Electrolytic Equilibria 231 18 Tonicity, Osmoticity, Osmolality, and Osmolarity 250 19 Chemical Kinetics 266 20 Interfacial Phenomena 280 21 Colloidal Dispersions 293 22 Coarse Dispersions 319 23 Rheology 338 Part 3 Pharmaceutical Chemistry 361 25 Organic Pharmaceutical Chemistry 361 25 Organic Pharmaceutical Chemistry 386 26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medicial Radionuclides 479 Part 4 Pharmaceutical Testing, Analysis, and Control 30	11	Metrology and Pharmaceutical Calculations
13 Molecular Structure, Properties, and States of Matter	12	Statistics
14 Complex Formation 186 15 Thermodynamics 201 16 Solutions and Phase Equilibria 211 17 Ionic Solutions and Electrolytic Equilibria 231 18 Tonicity, Osmoticity, Osmolality, and Osmolarity 250 19 Chemical Kinetics 266 20 Interfacial Phenomena 280 21 Colloidal Dispersions 293 22 Coarse Dispersions 293 23 Rheology 338 Part 3 Pharmaceutical Chemistry 361 25 Organic Pharmaceutical Chemistry 366 26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medicial Radionuclides 479 Part 4 Pharmaceutical Testing, Analysis, and Control 30 Analysis of Medicinals 495 31 Biological Testing 553 32 Clinical Analysis 565 33 Chromatography <	13	Molecular Structure, Properties, and States of Matter162
15 Thermodynamics 201 16 Solutions and Phase Equilibria 211 17 Ionic Solutions and Electrolytic Equilibria 231 18 Tonicity, Osmoticity, Osmolality, and Osmolarity 250 19 Chemical Kinetics 266 20 Interfacial Phenomena 280 21 Colloidal Dispersions 293 22 Coarse Dispersions 319 23 Rheology 338 Part 3 Pharmaceutical Chemistry 361 25 Organic Pharmaceutical Chemistry 366 26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medicial Radionuclides 479 Part 4 Pharmaceutical Testing, Analysis, and Control 30 30 Analysis of Medicinals 495 31 Biological Testing 553 32 Clinical Analysis 565 33 Chromatography 599 34 Instrumental	14	Complex Formation
16 Solutions and Phase Equilibria .211 17 tonic Solutions and Electrolytic Equilibria .231 18 Tonicity, Osmoticity, Osmolality, and Osmolarity .250 19 Chemical Kinetics .266 20 Interfacial Phenomena .280 21 Colloidal Dispersions .293 22 Coarse Dispersions .319 23 Rheology .338 Part 3 Pharmaceutical Chemistry 24 Inorganic Pharmaceutical Chemistry .361 25 Organic Pharmaceutical Chemistry .386 26 Natural Products .410 27 Drug Nomenclature—United States Adopted Names .443 28 Structure-Activity Relationship and Drug Design .468 29 Fundamentals of Medical Radionuclides .479 Part 4 Pharmaceutical Testing, Analysis, and Control	15	Thermodynamics
17 Ionic Solutions and Electrolytic Equilibria	16	Solutions and Phase Equilibria
18 Tonicity, Osmoticity, Osmolality, and Osmolanty 250 19 Chemical Kinetics 260 20 Interfacial Phenomena 280 21 Colloidal Dispersions 293 22 Coarse Dispersions 319 23 Rheology 338 Part 3 Pharmaceutical Chemistry 361 24 Inorganic Pharmaceutical Chemistry 366 25 Organic Pharmaceutical Chemistry 386 26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medical Radionuclides 479 Part 4 Pharmaceutical Testing, Analysis, and Control 30 30 Analysis of Medicinals 495 31 Biological Testing 553 32 Chinical Analysis 565 33 Chromatography 599 34 Instrumental Methods of Analysis 633 35 Dissolution 702 36 Separation <t< td=""><td>17</td><td>Ionic Solutions and Electrolytic Equilibria</td></t<>	17	Ionic Solutions and Electrolytic Equilibria
19 Chemical Kinetics 266 20 Interfacial Phenomena 280 21 Colloidal Dispersions 293 22 Coarse Dispersions 319 23 Rheology 338 Part 3 Pharmaceutical Chemistry 361 25 Organic Pharmaceutical Chemistry 386 26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medical Radionuclides 479 Part 4 Pharmaceutical Testing, Analysis, and Control 30 Analysis of Medicinals 495 31 Biological Testing 553 32 Clinical Analysis 565 33 Chromatography 599 34 Instrumental Methods of Analysis 633 35 Dissolution 672 Part 5 Pharmaceutical Manufacturing 702 36 Separation 691 37 Powders 702	18	Tonicity, Osmoticity, Osmolality, and Osmolarity
20 Interfacial Phenomena	19	Chemical Kinetics
21 Colloidal Dispersions	20	Interfacial Phenomena
22 Coarse Dispersions	21	Colloidal Dispersions
23 Rheology	22	Coarse Dispersions
Part 3 Pharmaceutical Chemistry 361 24 Inorganic Pharmaceutical Chemistry 386 26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medical Radionuclides 479 Part 4 Pharmaceutical Testing, Analysis, and Control 30 Analysis of Medicinals 495 31 Biological Testing 553 32 Clinical Analysis 565 33 Chromatography 599 34 Instrumental Methods of Analysis 633 35 Dissolution 672 Part 5 Pharmaceutical Manufacturing 691 36 Separation 702 37 Powders 702 38 Property-Based Drug Design and Preformulation 720 39 Solutions, Emulsions, Suspensions, and Extracts 745 40 Sterilization 776 41 Parenteral Preparations 802 42 Intravenous Admixtures	23	Rheology
24 Inorganic Pharmaceutical Chemistry	Part 3	Pharmaceutical Chemistry
25 Organic Pharmaceutical Chemistry .386 26 Natural Products .410 27 Drug Nomenclature—United States Adopted Names .443 28 Structure-Activity Relationship and Drug Design .468 29 Fundamentals of Medical Radionuclides .479 Part 4 Pharmaceutical Testing, Analysis, and Control 30 Analysis of Medicinals .495 31 Biological Testing .553 32 Clinical Analysis .565 33 Chromatography .599 34 Instrumental Methods of Analysis .633 35 Dissolution .672 Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Pre	24	Inorganic Pharmaceutical Chemistry
26 Natural Products 410 27 Drug Nomenclature—United States Adopted Names 443 28 Structure-Activity Relationship and Drug Design 468 29 Fundamentals of Medical Radionuclides 479 Part 4 Pharmaceutical Testing, Analysis, and Control 30 Analysis of Medicinals 495 31 Biological Testing 553 32 Clinical Analysis 565 33 Chromatography 599 34 Instrumental Methods of Analysis 633 35 Dissolution .672 Part 5 Pharmaceutical Manufacturing .702 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .8	25	Organic Pharmaceutical Chemistry
27 Drug Nomenclature—United States Adopted Names	26	Natural Products
28 Structure-Activity Relationship and Drug Design .468 29 Fundamentals of Medical Radionuclides .479 Part 4 Pharmaceutical Testing, Analysis, and Control 30 Analysis of Medicinals .495 31 Biological Testing .553 32 Clinical Analysis .565 33 Chromatography .599 34 Instrumental Methods of Analysis .633 35 Dissolution .672 Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929	27	Drug Nomenclature—United States Adopted Names 443
29 Fundamentals of Medical Radionuclides	28	Structure-Activity Relationship and Drug Design
Part 4Pharmaceutical Testing, Analysis, and Control30Analysis of Medicinals.49531Biological Testing.55332Clinical Analysis.56533Chromatography.59934Instrumental Methods of Analysis.63335Dissolution.672Part 5Pharmaceutical Manufacturing36Separation.69137Powders.70238Property-Based Drug Design and Preformulation.72039Solutions, Emulsions, Suspensions, and Extracts.74540Sterilization.77641Parenteral Preparations.80242Intravenous Admixtures.83743Ophthalmic Preparations.85044Medicated Topicals.87145Oral Solid Dosage Forms.88946Coating of Pharmaceutical Dosage Forms.92947Extended-Release and Targeted Drug Delivery Systems.9398The New Drug Approval Process and Clinical Trial Design.965	29	Fundamentals of Medical Radionuclides479
30 Analysis of Medicinals .495 31 Biological Testing .553 32 Clinical Analysis .565 33 Chromatography .599 34 Instrumental Methods of Analysis .633 35 Dissolution .672 Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929 77 Extended-Release and Targeted Drug Delivery Systems .939 87 The New Drug Approval Process and .965	Part 4	Pharmaceutical Testing, Analysis, and Control
31 Biological Testing .553 32 Clinical Analysis .565 33 Chromatography .599 34 Instrumental Methods of Analysis .633 35 Dissolution .672 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929 77 Extended-Release and Targeted Drug Delivery Systems .939 8 The New Drug Approval Process and	30	Analysis of Medicinals
32 Clinical Analysis .565 33 Chromatography .599 34 Instrumental Methods of Analysis .633 35 Dissolution .672 Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929 77 Extended-Release and Targeted Drug Delivery Systems .939 8 The New Drug Approval Process and .965	31	Biological Testing
33 Chromatography .599 34 Instrumental Methods of Analysis .633 35 Dissolution .672 Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929 77 Extended-Release and Targeted Drug Delivery Systems .939 8 The New Drug Approval Process and .965	32	Clinical Analysis
34 Instrumental Methods of Analysis .633 35 Dissolution .672 Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .702 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929 77 Extended-Release and Targeted Drug Delivery Systems .939 8 The New Drug Approval Process and	33	Chromatography
35 Dissolution .672 Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929 77 Extended-Release and Targeted Drug Delivery Systems .939 8 The New Drug Approval Process and .965	34	Instrumental Methods of Analysis
Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929 77 Extended-Release and Targeted Drug Delivery Systems .939 8 The New Drug Approval Process and	35	Dissolution
Part 5 Pharmaceutical Manufacturing 36 Separation .691 37 Powders .702 38 Property-Based Drug Design and Preformulation .720 39 Solutions, Emulsions, Suspensions, and Extracts .745 40 Sterilization .776 41 Parenteral Preparations .802 42 Intravenous Admixtures .837 43 Ophthalmic Preparations .850 44 Medicated Topicals .871 45 Oral Solid Dosage Forms .889 46 Coating of Pharmaceutical Dosage Forms .929 77 Extended-Release and Targeted Drug Delivery Systems .939 8 The New Drug Approval Process and		
36 Separation	Part 5	Pharmaceutical Manufacturing
37 Powders	36	Separation
38 Property-Based Drug Design and Preformulation	37	Powders
39 Solutions, Emulsions, Suspensions, and Extracts	38	Property-Based Drug Design and Preformulation
40 Sterilization 776 41 Parenteral Preparations 802 42 Intravenous Admixtures 837 43 Ophthalmic Preparations 850 44 Medicated Topicals 871 45 Oral Solid Dosage Forms 889 46 Coating of Pharmaceutical Dosage Forms 929 47 Extended-Release and Targeted Drug Delivery Systems 939 8 The New Drug Approval Process and 965	39	Solutions, Emulsions, Suspensions, and Extracts
41 Parenteral Preparations	40	Sterilization
42 Intravenous Admixtures	41	Parenteral Preparations
 Ophthalmic Preparations	42	Intravenous Admixtures
 Medicated Topicals	43	Ophthalmic Preparations
 Oral Solid Dosage Forms	14	Medicated Topicals
 Coating of Pharmaceutical Dosage Forms	15	Oral Solid Dosage Forms 889
 Extended-Release and Targeted Drug Delivery Systems939 The New Drug Approval Process and Clinical Tria Design	6	Coating of Pharmaceutical Dosage Forms 929
8 The New Drug Approval Process and Clinical Tria Design	7	Extended Peleare and Targeted Drug Delivery Systems 020
Clinical Tria Design	9	The New Drive Annual Descent and
		Clinical Tria Design

49	Biotechnology and Drugs
50	Aerosols
51	Quality Assurance and Control
52	Stability of Pharmaceutical Products
53	Bioavailability and Bioequivalency Testing
54	Plastic Packaging Materials
55	Pharmaceutical Necessities
Part 6	Pharmacokinetics and Pharmacodynamics
56	Diseases: Manifestations and Pathophysiology
57	Drug Absorption, Action, and Disposition
58	Basic Pharmacokinetics and Pharmacodynamics
59	Clinical Pharmacokinetics and Pharmacodynamics
60	Priniciples of Immunology
61	Adverse Drug Reactions and Clinical Toxicology
62	Pharmacogenomics
63	Pharmacokinetics/Pharmacodynamics in
	Drug Development
Part 7	Pharmaceutical and Medicinal Agents
64	Diagnostic Drugs and Reagents
65	Topical Drugs
66	Gastrointestinal and Liver Drugs1294
67	Blood, Fluids, Electrolytes, and Hematological Drugs 1318
68	Cardiovascular Drugs
69	Respiratory Drugs
70	Sympathomimetic Drugs
71	Cholinomimetic Drugs
72	Adrenergic Antagonists and Adrenergic
	Neuron Blocking Drugs
73	Antimuscarinic and Antispasmodic Drugs
74	Skeletal Muscle Relaxants
75	Diuretic Drugs
76	Uterine and Antimigraine Drugs
77	Hormones and Hormone Antagonists
78	General Anesthetics
79	Local Anesthetics
80	Antianxiety Agents and Hypnotic Drugs
81	Antiepileptic Drugs1501
82	Psychopharmacologic Agents
83	Analgesic, Antipyretic, and Anti-Inflammatory Drugs 1524
84	Histamine and Antihistaminic Drugs
85	Central Nervous System Stimulants
86	Antineoplastic Drugs
87	Immunoactive Drugs
88	Parasiticides
89	Immunizing Agents and Allergenic Extracts
90	Anti-Infectives
91	Enzymes
92	Nutrients and Associated Substances
93	Pesticides
Part 8	Pharmacy Practice

A Fundamentals of Pharmacy Practice

Application of Ethical Principles to Practice Dilemmas 1745
Technology and Automation
The Patient: Behavioral Determinants
Patient Communication
Patient Compliance
Drug Education

94 95

96

97 98 99

xxii CONTENTS

Δ

100	Professional Communications	
101	The Prescription	
102	Providing a Framework for Ensuring	
	Medication Use Safety	
103	Poison Control	
104	Drug Interactions	
105	Extemporaneous Prescription Compounding 1903	
106	Nuclear Pharmacy Practice 1012	
107	Nutrition in Pharmacy Practice	
108	Pharmacoepidemiology	
109	Surgical Supplies	
110	Health Accessories	
	1979	
	B Social, Behavioral, Economic, and Administrative Sciences	
111	Laws Governing Pharmacy	
112	Re-engineering Pharmacy Practice	
113	Pharmacoeconomics	
114	Community Pharmacy Economics	
115	Product Recalls and Water de Management 2082	
116	Marketing Pharmaceutical Care Services	

Documenting, Billing, and Reimbursement for **C** Patient Care Development of a Pharmacy Care Plan and 123 124 125 126 127 128 129 130 Aseptic Processing for Home Infusion Pharmaceuticals .2290 131 The Pharmacist's Role in Substance Use Disorders2303 Complementary and Alternative Medical Health Care . . 2318 132 Chronic Wound Care2342 133

117

118

119

120

121 122

DOCK Α R Μ Find authenticated court documents without watermarks at docketalarm.com.

all

c01 of spi

be ily io pusi (e m st

CE

5

C

el

pti pgjiii

Parenteral Preparations

Michael J Akers, PhD

Parenteral (Gk, para enteron, beside the intestine) dosage forms differ from all other drug dosage forms because they are injected directly into body tissue through the primary protective system of the human body, the skin, and mucous membranes. They must be exceptionally pure and free from physical, chemical, and biological contaminants. These requirements place a heavy responsibility on the pharmaceutical industry to practice current good manufacturing practices (cGMPs) in the manufacture of parenteral dosage forms and upon pharmacists and other health care professionals to practice good aseptic practices (GAPs) in dispensing them for administration to patients.

Certain pharmaceutical agents, particularly peptides, proteins, and many chemotherapeutic agents, can only be given parenterally because they are inactivated in the gastrointestinal tract when given by mouth. Parenterally administered drugs are relatively unstable and generally high potent drugs that require strict control of their administration to the patient. Because of the advent of biotechnology, parenteral products have grown in number and usage around the world.

This chapter will focus on the unique characteristics of parenteral dosage forms and the basic principles for formulating, packaging, manufacturing, and controlling the quality of these unique products. The references and bibliography at the end of this chapter contain the most up-to-date texts, book chapters, and review papers on parenteral product formulation, manufacture, and quality control.

OVERVIEW OF UNIQUE CHARACTERISTICS OF PARENTERAL DOSAGE FORMS

Parenteral products are unique from any other type of pharmaceutical dosage form for the following reasons:

- All products must be sterile.
- All products must be free from pyrogenic (endotoxin) contamination.
- Injectable solutions must be free from visible particulate matter. This includes reconstituted sterile powders.
- Products should be isotonic although strictness of isotonicity depends on the route of administration. Products to be administered into the cerebrospinal fluid must be isotonic. Ophthalmic products, while not parenteral, also must be isotonic. Products to be administered by bolus injection by routes other than intravenous (IV) essentially should be isotonic or at least very close to isotonicity. IV infusions must be isotonic.

 All products must be stable (not only chemically and physically by former but also "stable" microbiologically by All products must be static used in the microbiologically be all other dosage forms, but also "stable" microbiologically, ie, set all other dosage torms, but also visible particulation of the statistic of ity, freedom from pot throughout the shelflife of the product must be maintained through the discrete state of the products must be compatible (if applicable) with IV diluents de the drug products co-administered de the d

livery systems, and other drug products co-administered.

FORMULATION PRINCIPLES

Parenteral drugs are formulated as solutions, suspensions emulsions, liposomes, microspheres, nanosystems, and pow. ders to be reconstituted as solutions. This section will describe the components that are commonly used in parenteral formula tions focusing on solutions and freeze-dried products. General guidance also will be provided on appropriate selection of the finished sterile dosage form and initial approaches used to develop the optimal parenteral formulation.

VEHICLES

WATER-Since most liquid injections are quite dilute, the component present in the highest proportion is the vehicle. The vehicle of greatest importance for parenteral products is water. Water of suitable quality for compounding and rinsing product contact surfaces may be prepared either by distillation or by reverse osmosis, to meet United States Pharmacopeia (USP) specifications for Water for Injection (WFI). Only by these two methods is it possible to separate adequately various liquid. gas, and solid contaminating substances from water. These two methods for preparation of WFI and specifications for WFI are discussed later in this chapter. With the possible exception of freeze-drying, there is no unit operation more important and none more costly to install and operate than the one for the preparation of WFI.

WATER-MISCIBLE VEHICLES-A number of solvents that are miscible with water have been used as a portion of the vehicle in the formulation of parenterals. These solvents are used primarily to solubilize certain drugs in an aqueous rehice and to reduce hydrolysis. The most important solvents in this group are ethyl alcohol, liquid polyethylene glycol, and profi lene glycol. Ethyl alcohol is used particularly in the preparation of solutions of of solutions of cardiac glycosides and the glycols in solutions of barbiturates barbiturates, certain alkaloids, and certain antibiotics. Such preparations usually are given intramuscularly. There are in itations with the itations with the amount of these co-solvents that can be at ministered because and the solution of these co-solvents that can be at ministered because and the solution of these co-solvents that can be at ministered because a solution of these co-solvents that can be at ministered because a solution of these co-solvents that can be at ministered because a solution of these co-solvents that can be at ministered because a solution of these co-solvents that can be at ministered because a solution of these co-solvents that can be at ministered because a solution of these co-solvents that can be at ministered because a solution of the ministered because of toxicity concerns, greater potential in hemolysis, and not out it is a site of the site of t hemolysis, and potential for drug precipitation at the site of more d jection.¹ Formulation scientists needing to use one or more d these solvents must these solvents must consult the literature (eg, reference²) and toxicologists to account in the literature (eg, reference²) and toxicologists to ascertain the maximum amount of co-solvents

DOCKE

The author recognizes the long time contributions of Dr. Kenneth Avis. Dr. Avis died in January 1999. Dr. Avis authored this chapter in Remington since 1965. To honor his memory, the author has maintained most of his organization of this chapter with new material and revised information added where appropriate.

DOCKET



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

